Corporate
Altimmune Secures FDA Breakthrough Therapy Designation for MASH Drug Pemvidutide
5d ago
You're signed outSign in or to get full access.
A
Altimmune (ALT)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering Altimmune.